141 related articles for article (PubMed ID: 8217614)
41. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival.
Jimenez-Zepeda VH; Mikhael J; Winter A; Franke N; Masih-Khan E; Trudel S; Chen C; Kukreti V; Reece DE
Biol Blood Marrow Transplant; 2012 May; 18(5):773-9. PubMed ID: 22062804
[TBL] [Abstract][Full Text] [Related]
42. Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m(2)).
Palumbo A; Bringhen S; Bertola A; Cavallo F; Falco P; Massaia M; Bruno B; Rus C; Barbui A; Caravita T; Musto P; Pescosta N; Rossini F; Vignetti M; Boccadoro M
Leukemia; 2004 Jan; 18(1):133-8. PubMed ID: 14586481
[TBL] [Abstract][Full Text] [Related]
43. Hematopoietic stem cell transplants for multiple myeloma.
Tricot G; Jagannath S; Vesole DH; Bracy D; Desikan KR; Siegel D; Barlogie B
Leuk Lymphoma; 1996 Jun; 22(1-2):25-36. PubMed ID: 8724525
[TBL] [Abstract][Full Text] [Related]
44. Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: a multicenter, open label phase 1/2 study.
Petrucci MT; Levi A; Bringhen S; Scotti S; Gentilini F; Russo S; Siniscalchi A; Larocca A; Grammatico S; Boccadoro M; Foà R; Palumbo A
Cancer; 2013 Mar; 119(5):971-7. PubMed ID: 23096113
[TBL] [Abstract][Full Text] [Related]
45. Single-dose intravenous melphalan in advanced multiple myeloma.
Bäck H; Lindblad R; Rödjer S; Westin J
Acta Haematol; 1990; 83(4):183-6. PubMed ID: 2115714
[TBL] [Abstract][Full Text] [Related]
46. Phase I-II trial of high-dose melphalan in previously untreated stage III multiple myeloma: Cancer and Leukemia Group B study 8512.
Case DC; Coleman M; Gottlieb A; McCarroll K
Cancer Invest; 1992; 10(1):11-7. PubMed ID: 1735010
[TBL] [Abstract][Full Text] [Related]
47. Single high-dose etoposide and melphalan with non-cryopreserved autologous marrow rescue as primary therapy for relapsed, refractory and poor-prognosis Hodgkin's disease.
Seymour LK; Dansey RD; Bezwoda WR
Br J Cancer; 1994 Sep; 70(3):526-30. PubMed ID: 8080741
[TBL] [Abstract][Full Text] [Related]
48. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO).
Pönisch W; Mitrou PS; Merkle K; Herold M; Assmann M; Wilhelm G; Dachselt K; Richter P; Schirmer V; Schulze A; Subert R; Harksel B; Grobe N; Stelzer E; Schulze M; Bittrich A; Freund M; Pasold R; Friedrich T; Helbig W; Niederwieser D;
J Cancer Res Clin Oncol; 2006 Apr; 132(4):205-12. PubMed ID: 16402269
[TBL] [Abstract][Full Text] [Related]
49. High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial.
Vesole DH; Crowley JJ; Catchatourian R; Stiff PJ; Johnson DB; Cromer J; Salmon SE; Barlogie B
J Clin Oncol; 1999 Jul; 17(7):2173-9. PubMed ID: 10561273
[TBL] [Abstract][Full Text] [Related]
50. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.
Blanes M; Lahuerta JJ; González JD; Ribas P; Solano C; Alegre A; Bladé J; San Miguel JF; Sanz MA; de la Rubia J
Biol Blood Marrow Transplant; 2013 Jan; 19(1):69-74. PubMed ID: 22897964
[TBL] [Abstract][Full Text] [Related]
51. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs.
Martino M; Postorino M; Gallo GA; Messina G; Neri S; Piro E; Gentile M; Moscato T; Monteleone R; Fedele R; Mazzone C; Console G; Penna G; Alati C; Vincelli ID; Irrera G; Musolino C; Ronco F; Molica S; Morabito F
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):148-54. PubMed ID: 24417912
[TBL] [Abstract][Full Text] [Related]
52. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
53. Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation.
Comenzo RL; Hassoun H; Kewalramani T; Klimek V; Dhodapkar M; Reich L; Teruya-Feldstein J; Fleisher M; Filippa D; Nimer SD
Leukemia; 2006 Feb; 20(2):345-9. PubMed ID: 16319952
[TBL] [Abstract][Full Text] [Related]
54. Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients.
Farag S; Jeker B; Bacher U; Mansouri Taleghani B; Mueller BU; Novak U; Pabst T
Hematol Oncol; 2018 Oct; 36(4):671-678. PubMed ID: 30110717
[TBL] [Abstract][Full Text] [Related]
55. Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma.
Palumbo A; Avonto I; Bruno B; Falcone A; Scalzulli PR; Ambrosini MT; Bringhen S; Gay F; Rus C; Cavallo F; Falco P; Massaia M; Musto P; Boccadoro M
Clin Lymphoma Myeloma; 2006 May; 6(6):475-7. PubMed ID: 16796778
[TBL] [Abstract][Full Text] [Related]
56. Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescue. The Newcastle and Northern Region Lymphoma Group.
Taylor PR; Jackson GH; Lennard AL; Lucraft H; Proctor SJ
Br J Cancer; 1993 Feb; 67(2):383-7. PubMed ID: 8431371
[TBL] [Abstract][Full Text] [Related]
57. Continuous low dose of melphalan and prednisone in patients with multiple myeloma of very old age or severe associated disease.
Pulsoni A; Villivà N; Cavalieri E; Falcucci P; La Verde G; Matera R; Petrucci MT; Tosti ME; Mandelli F
Drugs Aging; 2002; 19(12):947-53. PubMed ID: 12495369
[TBL] [Abstract][Full Text] [Related]
58. Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma.
Baz R; Fanning S; Kunkel L; Gaballa S; Karam MA; Reed J; Kelly M; Hussein M
Leuk Lymphoma; 2007 Dec; 48(12):2338-44. PubMed ID: 18067008
[TBL] [Abstract][Full Text] [Related]
59. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.
Mark TM; Guarneri D; Forsberg P; Rossi A; Pearse R; Perry A; Pekle K; Tegnestam L; Greenberg J; Shore T; Gergis U; Mayer S; Van Besien K; Ely S; Jayabalan D; Sherbenou D; Coleman M; Niesvizky R
Biol Blood Marrow Transplant; 2017 Jun; 23(6):930-937. PubMed ID: 28285081
[TBL] [Abstract][Full Text] [Related]
60. Multicyclic, dose-intensive chemotherapy supported by hemopoietic progenitors in refractory myeloma patients.
Palumbo A; Pileri A; Triolo S; Omedè P; Bruno B; Ciravegna G; Galliano M; Frieri R; Boccadoro M
Bone Marrow Transplant; 1997 Jan; 19(1):23-9. PubMed ID: 9012927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
